Aquestive Therapeutics, Inc.
Anaphylm
Type I allergic reactions, including anaphylaxis
Resolved
99days ago
Advisory committee · Mar 30, 2026
What's at stake
An FDA advisory committee reviews Anaphylm for Type I allergic reactions, including anaphylaxis around Mar 30, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“On March 30, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing the receipt of preliminary comments and successful completion of an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) ”